Identification of challenges and a framework for implementation of the AMP/ASCO/CAP classification guidelines for reporting somatic variants

Objectives In 2017, AMP, ASCO and CAP jointly published the first formalized classification system for the interpretation and reporting of sequence variants in cancer. The challenges of incorporating new variant interpretation guidelines into existing, validated workflows have likely hampered adoption and implementation in labs with classification methods in place. Ambiguity in assigning clinical significance across guidelines is grounded in differential weighting of evidence used in variant assessment. Therefore, we undertook an internal process-improvement exercise to correlate the two classification schemes using historical laboratory data. Design and methods Existing clinical variant assignments from 40 consecutive oncology cases comprising 150 somatic variants were re-assessed according to the 2017 AMP/ASCO/CAP scheme. Approximately 50% of these were cancers of the gynecologic tract. Results Our laboratory-developed (GPS) classifications for ‘actionable’ variants and variants of uncertain clinical significance mapped consistently with the AMP/ASCO/CAP Tiers I-III. The majority of Level 1 variants were reclassified to Tier I (21/25; 84%) while all Level 2 and Level 4 variants were assigned to Tier II (9/9; 100%) and Tier III (17/17; 100%), respectively. The greatest variability was seen for GPS Level 3 variants, which was strongly influenced by TP53 interpretations. Ultimately, we found that most GPS Level 3 variants were classified as Tier III (77/99; 77.8%). Conclusions Our internally developed 5-level classifications mapped consistently with the proposed AMP/ASCO/CAP 4-Tiered system. As a result of this analysis, we can provide a framework for other labs considering a similar transition to the 2017 AMP/ASCO/CAP guidelines and a rationale for explaining specific discrepancies.

[1]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[2]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[3]  Bijal A. Parikh,et al.  Optimization of Population Frequency Cut-offs for Filtering Common Germline Polymorphisms from Tumor-Only Next-Generation Sequencing Data. , 2019, The Journal of molecular diagnostics : JMD.

[4]  M. Ychou,et al.  TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy , 2009, British Journal of Cancer.

[5]  H. Saka,et al.  Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors , 2019, Cancer science.

[6]  L. Mariani,et al.  FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. , 2008, Current cancer drug targets.

[7]  M. Espié,et al.  Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen , 2007, PLoS medicine.

[9]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[10]  Savita Shrivastava,et al.  Validation of a next-generation sequencing assay for clinical molecular oncology. , 2014, The Journal of molecular diagnostics : JMD.